secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syros Pharmaceuticals, Inc. (—)
CIK:        0001556263
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001193125-24-260421
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.02, 2.04, 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Syros terminates QIAGEN pact, defaults on $43.7M loan, cuts 94% of staff, replaces CEO
--------------------------------------------------------------------------------

- Phase 3 SELECT-MDS-1 trial failure triggers termination of QIAGEN companion diagnostic agreement.
- Oxford Finance declares $43.7M immediately due; Syros pays $33.5M, plans forbearance negotiations.
- Workforce reduced by ~94%; CEO Conley Chee, CFO Jason Haas, CMO David Roth terminated without cause.
- Board members Andrew Oh, Srinivas Akkaraju, Deborah Dunsire, and others resign; Gerald Quirk appointed CEO.
- Gerald Quirk, previously Chief Legal & Compliance Officer, becomes President & CEO effective Nov 22, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/0001193125-24-260421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1556263/000119312524260421/d874889d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-260421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer